Agilent Technologies (NYSE:A) had its price objective boosted by equities research analysts at Deutsche Bank from $80.00 to $85.00 in a research note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the medical research company’s stock. Deutsche Bank’s target price points to a potential upside of 10.71% from the stock’s current price.
A number of other research analysts have also commented on the company. ValuEngine lowered Agilent Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, October 23rd. Zacks Investment Research lowered Agilent Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, October 16th. Morgan Stanley increased their price objective on Agilent Technologies from $86.00 to $89.00 and gave the company an “overweight” rating in a report on Tuesday, November 20th. Cleveland Research lowered Agilent Technologies from a “buy” rating to a “neutral” rating in a report on Monday, November 12th. Finally, Needham & Company LLC initiated coverage on Agilent Technologies in a report on Wednesday, January 2nd. They set a “buy” rating and a $77.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Agilent Technologies has an average rating of “Buy” and a consensus price target of $82.00.
Shares of A traded up $0.70 during midday trading on Tuesday, reaching $76.78. 15,458 shares of the stock were exchanged, compared to its average volume of 1,960,018. Agilent Technologies has a 12-month low of $60.42 and a 12-month high of $76.69. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.29 and a quick ratio of 2.74. The company has a market capitalization of $24.08 billion, a PE ratio of 27.52, a price-to-earnings-growth ratio of 2.12 and a beta of 1.33.
Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Monday, November 19th. The medical research company reported $0.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.07. Agilent Technologies had a return on equity of 19.84% and a net margin of 6.43%. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period last year, the business earned $0.67 EPS. The business’s quarterly revenue was up 8.8% on a year-over-year basis. On average, equities research analysts expect that Agilent Technologies will post 3.04 earnings per share for the current fiscal year.
Agilent Technologies announced that its board has initiated a share buyback plan on Monday, November 19th that allows the company to repurchase $1.75 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 8.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 17,491 shares of the firm’s stock in a transaction that occurred on Wednesday, January 30th. The stock was sold at an average price of $75.00, for a total value of $1,311,825.00. Following the sale, the chief executive officer now owns 456,430 shares of the company’s stock, valued at approximately $34,232,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael R. Mcmullen sold 15,923 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $73.20, for a total value of $1,165,563.60. Following the completion of the sale, the chief executive officer now directly owns 492,546 shares in the company, valued at approximately $36,054,367.20. The disclosure for this sale can be found here. Insiders sold a total of 43,816 shares of company stock worth $3,242,727 in the last ninety days.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in A. Cantillon Capital Management LLC bought a new position in shares of Agilent Technologies during the 4th quarter worth approximately $200,867,000. Robecosam AG lifted its position in shares of Agilent Technologies by 40.4% during the 1st quarter. Robecosam AG now owns 791,151 shares of the medical research company’s stock worth $31,741,000 after buying an additional 227,764 shares during the period. Jennison Associates LLC bought a new position in shares of Agilent Technologies during the 2nd quarter worth approximately $212,000. J. Goldman & Company bought a new position in shares of Agilent Technologies during the 3rd quarter worth approximately $4,277,000. Finally, Wells Fargo & Company MN lifted its position in shares of Agilent Technologies by 0.5% during the 3rd quarter. Wells Fargo & Company MN now owns 1,424,764 shares of the medical research company’s stock worth $67,093,000 after buying an additional 6,539 shares during the period.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Featured Article: Beta
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.